CONTEXT: Despite developments in the medical management of metastatic breast cancer, little is known about the quality of life (QoL) and experience of care in women with it. OBJECTIVES: To explore QoL, experience of care, and support needs of women living with metastatic breast cancer in the U.K. METHODS: Questionnaire-based, cross-sectional study, undertaken in two U.K. cancer centers and online via the Breast Cancer Care website, assessing QoL and experience of care in 235 women with metastatic breast cancer. RESULTS: QoL was assessed using the Functional Assessment of Cancer Therapy--Breast QoL measure. Overall, QoL was low (mean 89.0, standard deviation 21.8) for total score. Low scores were seen uniformly in physical, social, emotional, and functional well-being domains. Symptom burden was a significant problem, with over one-third of women (34%) reporting high levels of pain and other uncontrolled symptoms. In multiple regression analysis, social well-being was significantly better for older women (P<0.001) but was lower in those with bone metastases only (P=0.002). Functional well-being was significantly higher in women without children (P=0.004). Satisfaction with experience of care was low and appeared to be predominantly in the hospital setting, with little evidence of involvement of general practitioners and palliative care services. CONCLUSION: Despite improvements in treatment and survival of women with metastatic breast cancer, this group reports high symptom burden and dissatisfaction with elements of their care, indicating that alternative models of service delivery should be explored.
CONTEXT: Despite developments in the medical management of metastatic breast cancer, little is known about the quality of life (QoL) and experience of care in women with it. OBJECTIVES: To explore QoL, experience of care, and support needs of women living with metastatic breast cancer in the U.K. METHODS: Questionnaire-based, cross-sectional study, undertaken in two U.K. cancer centers and online via the Breast Cancer Care website, assessing QoL and experience of care in 235 women with metastatic breast cancer. RESULTS: QoL was assessed using the Functional Assessment of Cancer Therapy--Breast QoL measure. Overall, QoL was low (mean 89.0, standard deviation 21.8) for total score. Low scores were seen uniformly in physical, social, emotional, and functional well-being domains. Symptom burden was a significant problem, with over one-third of women (34%) reporting high levels of pain and other uncontrolled symptoms. In multiple regression analysis, social well-being was significantly better for older women (P<0.001) but was lower in those with bone metastases only (P=0.002). Functional well-being was significantly higher in women without children (P=0.004). Satisfaction with experience of care was low and appeared to be predominantly in the hospital setting, with little evidence of involvement of general practitioners and palliative care services. CONCLUSION: Despite improvements in treatment and survival of women with metastatic breast cancer, this group reports high symptom burden and dissatisfaction with elements of their care, indicating that alternative models of service delivery should be explored.
Authors: Jasmine Yee; Glen M Davis; Jane M Beith; Nicholas Wilcken; David Currow; Jon Emery; Jane Phillips; Andrew Martin; Rina Hui; Michelle Harrison; Eva Segelov; Sharon L Kilbreath Journal: J Cancer Surviv Date: 2014-07-02 Impact factor: 4.442
Authors: Jennifer A Shin; Areej El-Jawahri; Amanda Parkes; Stephen M Schleicher; Helen P Knight; Jennifer S Temel Journal: J Palliat Med Date: 2016-04-28 Impact factor: 2.947
Authors: Timothy J Williamson; Susan M Love; Jessica N Clague DeHart; Alexandra Jorge-Miller; Leah Eshraghi; Heather Cooper Ortner; Annette L Stanton Journal: Breast Cancer Res Treat Date: 2018-05-16 Impact factor: 4.872
Authors: Patricia Sheean; Lauren Matthews; Alexis Visotcky; Anjishnu Banerjee; Andrea Moosreiner; Kimberly Kelley; Christopher R Chitambar; Paula E Papanek; Melinda Stolley Journal: Breast Cancer Res Treat Date: 2021-03-19 Impact factor: 4.624
Authors: Marloes E Clarijs; Jacob Thurell; Friedrich Kühn; Carin A Uyl-de Groot; Elham Hedayati; Maria M Karsten; Agnes Jager; Linetta B Koppert Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639
Authors: Caroline Eyles; Geraldine M Leydon; Caroline J Hoffman; Ellen R Copson; Philip Prescott; Maria Chorozoglou; George Lewith Journal: Integr Cancer Ther Date: 2014-08-26 Impact factor: 3.279
Authors: Charles Cleeland; Roger von Moos; Mark S Walker; Yuanyuan Wang; Jianqing Gao; Mariana Chavez-MacGregor; Alexander Liede; Jorge Arellano; Arun Balakumaran; Yi Qian Journal: Support Care Cancer Date: 2016-03-29 Impact factor: 3.603
Authors: Suzanne A Eccles; Eric O Aboagye; Simak Ali; Annie S Anderson; Jo Armes; Fedor Berditchevski; Jeremy P Blaydes; Keith Brennan; Nicola J Brown; Helen E Bryant; Nigel J Bundred; Joy M Burchell; Anna M Campbell; Jason S Carroll; Robert B Clarke; Charlotte E Coles; Gary J R Cook; Angela Cox; Nicola J Curtin; Lodewijk V Dekker; Isabel dos Santos Silva; Stephen W Duffy; Douglas F Easton; Diana M Eccles; Dylan R Edwards; Joanne Edwards; D Evans; Deborah F Fenlon; James M Flanagan; Claire Foster; William M Gallagher; Montserrat Garcia-Closas; Julia M W Gee; Andy J Gescher; Vicky Goh; Ashley M Groves; Amanda J Harvey; Michelle Harvie; Bryan T Hennessy; Stephen Hiscox; Ingunn Holen; Sacha J Howell; Anthony Howell; Gill Hubbard; Nick Hulbert-Williams; Myra S Hunter; Bharat Jasani; Louise J Jones; Timothy J Key; Cliona C Kirwan; Anthony Kong; Ian H Kunkler; Simon P Langdon; Martin O Leach; David J Mann; John F Marshall; Lesley Martin; Stewart G Martin; Jennifer E Macdougall; David W Miles; William R Miller; Joanna R Morris; Sue M Moss; Paul Mullan; Rachel Natrajan; James P B O'Connor; Rosemary O'Connor; Carlo Palmieri; Paul D P Pharoah; Emad A Rakha; Elizabeth Reed; Simon P Robinson; Erik Sahai; John M Saxton; Peter Schmid; Matthew J Smalley; Valerie Speirs; Robert Stein; John Stingl; Charles H Streuli; Andrew N J Tutt; Galina Velikova; Rosemary A Walker; Christine J Watson; Kaye J Williams; Leonie S Young; Alastair M Thompson Journal: Breast Cancer Res Date: 2013-10-01 Impact factor: 6.466